Conference
Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi).
Abstract
277
Background: Epidemiologic studies support an association between statin use and improved prostate cancer specific mortality. Several different biologic mechanisms for such an effect have been proposed, including a potential role in reducing androgen precursor bioavailability. It is hypothesized that statins may therefore improve outcomes specifically in patients treated with the CYP17 inhibitor Abi. Di Lorenzo (2017) …
Authors
Gordon JA; Eigl BJ; Locke JA; Pond GR; Chehroudi C; Khalaf D; Chi KN; Cox ME
Volume
36
Pagination
pp. 277-277
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2018
DOI
10.1200/jco.2018.36.6_suppl.277
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X